J. Bussink et al., Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts, effects of carbogen and nicotinamide, RADIOTH ONC, 50(2), 1999, pp. 173-184
Citations number
45
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Background and purpose: A better understanding of the vascular architecture
and the microenvironmental parameters (VAMP) will allow the identification
of tumours that can be more effectively treated by intensified fractionate
d radiotherapy or modifiers of bloodflow and oxygenation or combinations of
these approaches.
Materials and methods: Proliferation (BrdUrd), vascular architecture (endot
helial marker), perfusion (Hoechst 33342) and oxygenation (NITP) were studi
ed in two human laryngeal squamous cell carcinoma tumour lines grown as xen
ografts in nude mice. The effects of carbogen and nicotinamide on these par
ameters were evaluated.
Results: Carbogen treatment resulted in a decrease of the number of perfuse
d blood vessels from 66% to 55% in one of the two tumour lines. In this tum
our line nicotinamide prevented this reduction of tumour blood flow by carb
ogen. In both tumour lines the labelling index (LI) decreased after treatme
nt with carbogen for 1 h, from 11-13% to 5-7%. Both tumour Lines showed a d
rastic reduction of hypoxia by carbogen alone or by carbogen plus nicotinam
ide.
Conclusions: In both laryngeal squamous cell carcinoma xenograft tumour lin
es carbogen was very effective in reducing diffusion limited hypoxia. Only
in one of the two tested tumour lines carbogen also caused a reduction of t
umour blood perfusion, which could be compensated for by nicotinamide. In a
ddition, carbogen reduced tumour cell proliferation. The fact that differen
ces in response to nicotinamide and carbogen were observed and that they ca
n be studied in vivo provides a basis for further development of a 'predict
ive profile' which will guide the clinician to select the optimal treatment
for individual patients or groups of patients. (C) 1999 Elsevier Science I
reland Ltd. All rights reserved.